Artesunate/pyronaridine, sold under the brand name Pyramax, is a fixed dose combination medication for the treatment of malaria. It can be used for malaria of both the P. falciparum and P. vivax types. It combines artesunate and pyronaridine. It is taken by mouth.
The combination is generally well tolerated. Side effects may include headache, vomiting, or cough. Use in those with severe liver disease or kidney disease is not recommended. Use is not generally recommended in early pregnancy. However, there are no other options and if treatment may save the mother's life it may be used. The two components work by different mechanisms.
It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. In 2010 the wholesale cost of a course of treatment in the developing world was between 0.55 and 2.18 USD.
A 2014 review found that the combination compared well to artemether/lumefantrine. Benefits also appear similar to mefloquine together with artesunate. It is not recommended for the prevention of malaria.
- "Pyramax 180 mg/60 mg Film-coated tablet" (PDF). EMA. Retrieved 13 December 2017.
- "Application for inclusion in the WHO Model List of essential medicines" (PDF). WHO. Nov 2010. Retrieved 29 June 2017.
- "WHO Model List of Essential Medicines (20th List)" (PDF). World Health Organization. March 2017. Retrieved 29 June 2017.
- Bukirwa, H; Unnikrishnan, B; Kramer, CV; Sinclair, D; Nair, S; Tharyan, P (4 March 2014). "Artesunate plus pyronaridine for treating uncomplicated Plasmodium falciparum malaria". The Cochrane Database of Systematic Reviews (3): CD006404. doi:10.1002/14651858.CD006404.pub2. PMC . PMID 24596021.